Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$14.95 -4.6%	$8.98	$4.92 ▼ $28.60	$8.57M	1.34	174,414 shs	90,341 shs
VOR Vor Biopharma	$2.21 -7.1%	$0.78	$0.13 ▼ $3.29	$276.16M	2.04	4.93 million shs	7.12 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	+3.23%	-45.02%	+150.72%	+173.82%	+108.93%
VOR Vor Biopharma	+12.26%	+3.03%	+1,054.22%	+266.15%	+138.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTL Artelo Biosciences	2.5026 of 5 stars	3.8	3.0	0.0	0.0	2.4	0.0	0.6
VOR Vor Biopharma	3.5338 of 5 stars	4.3	5.0	0.0	0.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTL Artelo Biosciences	3.60	Strong Buy	$25.00	67.22% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	154.69% Upside

Current Analyst Ratings Breakdown

Latest ARTL, AFA, EGH, VOR, and DGH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/6/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	$5.31 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTL Artelo Biosciences	-$9.83M	-$17.94	0.00	N/A	N/A	N/A	-226.99%	-164.61%	8/12/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARTL, AFA, EGH, VOR, and DGH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ARTL Artelo Biosciences	-$0.78	-$4.32	-$3.54	-$0.72	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTL Artelo Biosciences	N/A	0.49	0.49
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTL Artelo Biosciences	0.87%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ARTL Artelo Biosciences	0.83%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTL Artelo Biosciences	5	550,000	542,000	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

ARTL, AFA, EGH, VOR, and DGH Headlines

Recent News About These Companies

Vor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing Zuraw

4 hours ago | quiverquant.comQ

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

5 hours ago | globenewswire.com

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

July 17 at 8:30 AM | globenewswire.com

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)

July 10, 2025 | americanbankingnews.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63

July 8, 2025 | americanbankingnews.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30, 2025 | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30, 2025 | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30, 2025 | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
By Thomas Hughes | July 16, 2025
View This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
Sizzling Insider Buys for Your High-Yield Watchlist
By Thomas Hughes | July 8, 2025
View Sizzling Insider Buys for Your High-Yield Watchlist

ARTL, AFA, EGH, VOR, and DGH Company Descriptions

Artelo Biosciences NASDAQ:ARTL

$14.95 -0.72 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$14.47 -0.48 (-3.18%)

As of 07:14 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Vor Biopharma NYSE:VOR

$2.21 -0.17 (-7.14%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.04 (+1.58%)

As of 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time